COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #198 of 260
11/28 Late treatment study
Rodriguez-Gonzalez et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106249 (Peer Reviewed)
COVID-19 in hospitalized patients in Spain: a cohort study in Madrid
Source   PDF   Share   Tweet
Retrospective 1255 patients in Spain showing lower mortality with HCQ. Subject to confounding by indication.

Rodriguez-Gonzalez et al., 11/28/2020, retrospective, Spain, Europe, peer-reviewed, 20 authors.
risk of death, 22.8% lower, RR 0.77, p = 0.26, treatment 251 of 1148 (21.9%), control 17 of 60 (28.3%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.